Morgan Stanley Gelesis Holdings, Inc. Transaction History

Morgan Stanley

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.11 - $0.52 $698 - $3,304	6,354 Added 103.43%	12,497 $1,000
Q4 2022 Feb 14, 2023	SELL	$0.22 - $0.51 $1,715 - $3,976	-7,797 Reduced 55.93%	6,143 $1,000
Q3 2022 Nov 14, 2022	BUY	$0.08 - $1.34 $157 - $2,635	1,967 Added 16.43%	13,940 $15,000
Q2 2022 Oct 27, 2022	BUY	N/A	8,448 Added 239.66%	11,973 $19,000
Q2 2022 Aug 15, 2022	BUY	N/A	8,448 Added 239.66%	11,973 $19,000
Q1 2022 Oct 27, 2022	SELL	N/A	-8,448 Reduced 70.56%	3,525 $16,000
Q1 2022 May 13, 2022	BUY	N/A	3,525 New	3,525 $16,000

4.7K

Ticker GLS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,946,704
Market Cap $1.46M
Description
Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipelin...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.